GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » Beta

Durata Therapeutics (FRA:DTA) Beta : N/A (As of May. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-06), Durata Therapeutics's Beta is Not available.


Durata Therapeutics Beta Historical Data

The historical data trend for Durata Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics Beta Chart

Durata Therapeutics Annual Data
Trend Dec11 Dec12 Dec13
Beta
- - -

Durata Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Durata Therapeutics's Beta

For the Biotechnology subindustry, Durata Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durata Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's Beta falls into.



Durata Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Durata Therapeutics  (FRA:DTA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Durata Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines